» Articles » PMID: 19157721

Treatment Parameters and Outcome in 680 Treatments of Internal Radiation with Resin 90Y-microspheres for Unresectable Hepatic Tumors

Abstract

Purpose: Radioembolization (RE) using (90)Y-microspheres is an effective and safe treatment for patients with unresectable liver malignancies. Radiation-induced liver disease (RILD) is rare after RE; however, greater understanding of radiation-related factors leading to serious liver toxicity is needed.

Methods And Materials: Retrospective review of radiation parameters was performed. All data pertaining to demographics, tumor, radiation, and outcomes were analyzed for significance and dependencies to develop a predictive model for RILD. Toxicity was scored using the National Cancer Institute Common Toxicity Criteria Adverse Events Version 3.0 scale.

Results: A total of 515 patients (287 men; 228 women) from 14 US and 2 EU centers underwent 680 separate RE treatments with resin (90)Y-microspheres in 2003-2006. Multifactorial analyses identified factors related to toxicity, including activity (GBq) Selective Internal Radiation Therapy delivered (p < 0.0001), prescribed (GBq) activity (p < 0.0001), percentage of empiric activity (GBq) delivered (p < 0.0001), number of prior liver treatments (p < 0.0008), and medical center (p < 0.0001). The RILD was diagnosed in 28 of 680 treatments (4%), with 21 of 28 cases (75%) from one center, which used the empiric method.

Conclusions: There was an association between the empiric method, percentage of calculated activity delivered to the patient, and the most severe toxicity, RILD. A predictive model for RILD is not yet possible given the large variance in these data.

Citing Articles

Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer.

Anbari Y, Veerman F, Keane G, Braat A, Smits M, Bruijnen R J Interv Med. 2024; 6(4):153-159.

PMID: 38312126 PMC: 10831371. DOI: 10.1016/j.jimed.2023.09.001.


Safety and Efficacy of Selective Internal Radionuclide Therapy with Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization.

Bellendorf A, Mader N, Mueller S, Ezziddin S, Bockisch A, Grafe H Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256934 PMC: 10819448. DOI: 10.3390/ph17010101.


Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.

Braat M, Ebbers S, Alsultan A, Neek A, Bruijnen R, Smits M Diagnostics (Basel). 2023; 13(24).

PMID: 38132236 PMC: 10742749. DOI: 10.3390/diagnostics13243652.


AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization.

Busse N, Al-Ghazi M, Abi-Jaoudeh N, Alvarez D, Ayan A, Chen E J Appl Clin Med Phys. 2023; 25(2):e14157.

PMID: 37820316 PMC: 10860558. DOI: 10.1002/acm2.14157.


Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review.

Gonzalez-Flores E, Zambudio N, Pardo-Moreno P, Gonzalez-Astorga B, de la Rua J, Trivino-Ibanez E Clin Transl Oncol. 2023; 26(4):851-863.

PMID: 37747636 PMC: 10981623. DOI: 10.1007/s12094-023-03299-y.